Objective and methods: 83 patients infected with P.vivax malaria were divided randomly into two groups. 51 patients were treated with CV8 and 32 patients were treated with Chlo + Pri. Results: The mean time for disolving fever was 20.1 hours for CV8 group and 21.0 hours for Chlo + Pri group, the difference has no statistic significance with P>0.05. The mean parasite clearance time was 30.3 hours and 31.0 hours for CV8 and Chlo + Pri groups. respectively, the difference has no statistic significance with P>0.05. The relapse parasite rate was 3.9 % in CV8 group, highter than that in Chlo + Pri group (3.1%) of , the difference has no statistic significance with P>0.05. Conclusion: CV8 can be used for P. vivax malaria patients in the hyper-epidemic remote areas.
Malaria ; Primaquine ; Malaria ; Falciparum

224 patients with uncomplicated P. falciparum malaria were randomly devided into two groups receiving CV8 treatment (123 patients) and artesunate+primaquine (As+Pri) (101 patients). Results: The lately recurrence rate of CV8 treatment was 3.3% and of As+Pri was 17.8%, the difference had statistic significance (p<0.05). Mean time for fever clearance of CV8 was 22.5 hours, was the same as AS+Pri (21.8 hours). The inhibitory gametocidel effect on CV8 on P.falciparum has been seen and it help elimination of dissermination. The side effects such as nausea (13.8%), vomitting (4.9%) in CV8 treated groups were the same in AS+Pri groups. These effects were often self-limited. There were no hemoglobinuria case.
Malaria, Primaquine, Malaria, Falciparum

In Korea, Plasmodium vivax (P. vivax) is the most common agent of malaria infection. However, as travel to regions where malaria is endemic increases, so do the numbers of Plasmodium falciparum and mixed infections. P. falciparum predominates, while P. vivax is rare in west-central Africa. We report on a case of mixed malaria infection with severe hemolytic anemia caused by P. falciparum and P. vivax in a 38-year-old man after traveling to Angola. A diagnosis of P. falciparum malaria was made by microscopic examination. However, both P. vivax and P. falciparum were detected by the polymerase chain reaction (PCR). As a radical cure P. vivax, the patient was treated with mefloquine, artemether, and primaquine. Both P. falciparum and P. vivax had disappeared from peripheral blood by admission day 4, however, low grade fever and headache persisted, and his hemoglobin and hematocrit levels were depleted. A peripheral blood smear was negative for both P. vivax and P. falciparum; however, a direct anti-globulin test and anti-nuclear antibody test were positive, suggesting immune hemolytic anemia. After conservative treatment, which included a transfusion with packed red blood cells (RBC), his symptoms and signs showed improvement and laboratory findings were normalized.
Adult ; Africa ; Anemia, Hemolytic ; Angola ; Artemisinins ; Coinfection ; Erythrocytes ; Fever ; Headache ; Hematocrit ; Hemoglobins ; Humans ; Korea ; Malaria ; Mefloquine ; Plasmodium falciparum ; Plasmodium vivax ; Polymerase Chain Reaction ; Primaquine

We experienced a case of mixed infection with Plasmodium falciparum and P. vivax in a 48-year old Korean man. He returned to Korea from Papua New Guinea, where he worked for 20 days. Approximately one month after return to Korea, he developed high fever and myalgia. Malaria was suspected and he was admitted to our hospital. The peripheral blood smear demonstrated ring forms of P. falciparum. He was treated with quinine and doxycycline successfully. However, fever and myalgia reappeared five months later. This time, the peripheral blood smear showed gametocytes of P. vivax, while indirect immunofluorescence antibody test revealed high titers to both P. vivax and P. falciparum. He was treated with chloroquine and primaquine. Three months later, vivax malaria recurred again; he was treated with chloroquine and higher dose of primaquine. The patient was well after 6 months of follow-up. We hereby report a case of mixed malarial infections with a review of literatures.
Chloroquine ; Coinfection ; Doxycycline ; Fever ; Fluorescent Antibody Technique, Indirect ; Follow-Up Studies ; Humans ; Korea ; Malaria ; Malaria, Vivax ; Middle Aged ; Myalgia ; Papua New Guinea ; Plasmodium falciparum* ; Plasmodium vivax* ; Plasmodium* ; Primaquine ; Quinine